Advances In Breast Cancer Therapy
Abstract
A total of two hundred eight (208) specimens have been submitted to Precision for this study. One hundred twenty-two (122) subjects have been enrolled in this study to date. Out of those patients, thirty-five (35) were discontinued. Thirty-two (32) subjects were discontinued for not having a chemoresponse assay result, two (2) subjects were discontinued for being lost to follow-up, and one (1) subject was discontinued for an adverse experience on her SOC chemotherapy. Five (5) subjects are considered to be pre-enrolled at the time of this report. There are no safety issues (anticipated or unanticipated) to report for a study-related procedure. A total of twenty-nine (29) principal investigators have now been approved by the DoD to participate in this study. Since beginning the study, two (2) of these sites have been closed. Precision is currently working with eleven (11) US Oncology research sites and 16 Precision-managed sites. An additional one (1) site is in the start-up stage. Precision held its second investigator meeting in conjunction with the ASBS Conference in Washington DC on April 30, 2011. Subject screening and monitoring activities are ongoing. Strategies for increasing enrollment have been implemented and new sites are currently being identified to replace the sites that have been closed.
Document Details
- Document Type
- Technical Report
- Publication Date
- Sep 01, 2011
- Accession Number
- ADA562073
Entities
People
- Hong Ma